{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T16:55:08Z","timestamp":1774889708904,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100690","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T07:50:23Z","timestamp":1676015423000},"page":"100690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study"],"prefix":"10.1016","volume":"35","author":[{"given":"Jean-Marc","family":"Phelip","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Jean","family":"Souquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Hacini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Chehimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryma","family":"Bennoune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Tredan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2023.100690_bib0001","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2023.100690_bib0002","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0003","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1186\/s12885-015-1651-9","article-title":"Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey","volume":"15","author":"Sakai","year":"2015","journal-title":"BMC Cancer"},{"issue":"2011","key":"10.1016\/j.ctarc.2023.100690_bib0004","first-page":"8","volume":"47","author":"Aapro","year":"1990","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.ctarc.2023.100690_bib0005","first-page":"26","article-title":"Prise en charge et pr\u00e9vention de l\u2019\u00e9pisode infectieux lors des neutrop\u00e9nies f\u00e9briles","volume":"158","author":"Lavigne-Lissalde","year":"2007","journal-title":"SPECTRA Biol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0006","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0007","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2217\/fon-2018-0814","article-title":"Chemotherapy-induced neutropenia\/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study","volume":"15","author":"Ludwig","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2022.40.4_suppl.011","article-title":"Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT\/IDEA pooled analysis of 11 trials","volume":"40","author":"Gallois","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0009","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1200\/JOP.2012.000810","article-title":"Improving the relative dose intensity of systemic chemotherapy in a community-based outpatient cancer center","volume":"9","author":"Vavra","year":"2013","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ctarc.2023.100690_bib0010","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","article-title":"The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Lyman","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0011","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1200\/JCO.2012.44.6229","article-title":"Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia","volume":"31","author":"Aarts","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0012","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"Klastersky","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0013","first-page":"841","article-title":"Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients","volume":"16","author":"de Souza Viana","year":"2008","journal-title":"Support. Care Cancer."},{"key":"10.1016\/j.ctarc.2023.100690_bib0014","first-page":"1819","article-title":"Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study, support. care cancer off","volume":"25","author":"Bokemeyer","year":"2017","journal-title":"J. Multinatl. Assoc. Support. Care Cancer."},{"key":"10.1016\/j.ctarc.2023.100690_bib0015","first-page":"911","article-title":"Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study), Support. Care Cancer Off","volume":"24","author":"Gasc\u00f3n","year":"2016","journal-title":"J. Multinatl. Assoc. Support. Care Cancer."},{"key":"10.1016\/j.ctarc.2023.100690_bib0016","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.critrevonc.2007.01.008","article-title":"Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel","volume":"63","author":"Gridelli","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ctarc.2023.100690_bib0017","first-page":"2309","article-title":"Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?","volume":"24","author":"Weycker","year":"2016","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223000114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:38Z","timestamp":1762842938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223000114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":17,"alternative-id":["S2468294223000114"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100690","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100690"}}